Matches in Wikidata for { <http://www.wikidata.org/entity/Q64187970> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q64187970 description "clinical trial" @default.
- Q64187970 description "ensayu clínicu" @default.
- Q64187970 description "klinisch onderzoek" @default.
- Q64187970 description "клінічне випробування" @default.
- Q64187970 name "Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Par" @default.
- Q64187970 type Item @default.
- Q64187970 label "Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Par" @default.
- Q64187970 prefLabel "Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Par" @default.
- Q64187970 P1050 Q64187970-31D41778-04F9-4240-B484-4908CF90B436 @default.
- Q64187970 P1132 Q64187970-BF92B9CE-C47D-4A49-8C85-4202C2587791 @default.
- Q64187970 P1476 Q64187970-FDA0032A-8EA2-4451-96D8-58B5C47C1C96 @default.
- Q64187970 P17 Q64187970-514CD482-9F63-4FC2-8A8F-E736BF208B0F @default.
- Q64187970 P17 Q64187970-516299BF-3FE6-41EA-A4EE-0093EB8DFD4A @default.
- Q64187970 P17 Q64187970-6A8695F7-1272-48AA-8410-F0D5BD41A973 @default.
- Q64187970 P17 Q64187970-6D5D7ADA-29C5-4791-A0DF-219C9D23BA56 @default.
- Q64187970 P17 Q64187970-7449FC7A-6446-4B84-A426-541CA866774D @default.
- Q64187970 P17 Q64187970-9899C9E6-ECA2-46B3-B162-CAB834B79952 @default.
- Q64187970 P17 Q64187970-C3DBC9EE-0B71-449D-A6FA-B908A55D305C @default.
- Q64187970 P17 Q64187970-C62045E7-2294-4774-913E-F655B14CE9D8 @default.
- Q64187970 P17 Q64187970-DFE65833-6D52-4C39-9235-A26DAEE2A434 @default.
- Q64187970 P2899 Q64187970-B316DC6C-7864-4361-91CD-569A7C442E20 @default.
- Q64187970 P3098 Q64187970-4C9B5D56-4E2E-4680-B116-1C201A740722 @default.
- Q64187970 P31 Q64187970-FD38E71F-21B3-43B3-A6B5-CBF2DFD47ABD @default.
- Q64187970 P4135 Q64187970-90B75B30-BBB7-4EC4-91DB-5F94969A325C @default.
- Q64187970 P4844 Q64187970-8296DE4F-F9E6-4981-90A4-37A85B4215CF @default.
- Q64187970 P580 Q64187970-C578DEE2-563B-403B-8C91-09368490FA2C @default.
- Q64187970 P582 Q64187970-9AC44F6A-F71B-4E4C-A06E-AF046216E037 @default.
- Q64187970 P6099 Q64187970-50D9A0D8-2F8E-45D6-A50A-59E049A83102 @default.
- Q64187970 P6153 Q64187970-115F20BA-A687-483A-9744-E60A248EA821 @default.
- Q64187970 P6153 Q64187970-11909399-7F6C-4A8D-8D9D-1521F343BE4F @default.
- Q64187970 P6153 Q64187970-2A39C6BD-5C1C-48EC-9101-C93BF5BAA09A @default.
- Q64187970 P6153 Q64187970-4AB1572C-4457-4F6F-8656-C85C2BB56902 @default.
- Q64187970 P6153 Q64187970-54AA9E23-0E40-48C4-BB6B-EEFA009BE0A5 @default.
- Q64187970 P6153 Q64187970-6C2D707C-271C-4D93-9770-E0D7AD69E3F2 @default.
- Q64187970 P6153 Q64187970-6F21EBED-528A-427C-A395-7A9CE0282142 @default.
- Q64187970 P6153 Q64187970-783762B6-50E3-48CB-8169-90DE2A8204F4 @default.
- Q64187970 P6153 Q64187970-7BFDCF99-6848-43D2-AFEB-415F699FAE81 @default.
- Q64187970 P6153 Q64187970-7D3D407A-64EC-40D7-B409-26CB5124F76E @default.
- Q64187970 P6153 Q64187970-9ABFF572-0237-4EAF-8DAF-91829D2AC13F @default.
- Q64187970 P6153 Q64187970-AB736678-BE1D-4558-8504-856CB4CEF528 @default.
- Q64187970 P6153 Q64187970-F73ADE6A-2052-43AE-893F-5D64EEEB9467 @default.
- Q64187970 P8363 Q64187970-0FC77FA0-FC99-48A0-9D25-3EA74A108AA3 @default.
- Q64187970 P1050 Q944142 @default.
- Q64187970 P1132 "+145" @default.
- Q64187970 P1476 "A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide" @default.
- Q64187970 P17 Q142 @default.
- Q64187970 P17 Q155 @default.
- Q64187970 P17 Q219 @default.
- Q64187970 P17 Q28 @default.
- Q64187970 P17 Q29 @default.
- Q64187970 P17 Q30 @default.
- Q64187970 P17 Q31 @default.
- Q64187970 P17 Q36 @default.
- Q64187970 P17 Q38 @default.
- Q64187970 P2899 "+12" @default.
- Q64187970 P3098 "NCT03185819" @default.
- Q64187970 P31 Q30612 @default.
- Q64187970 P4135 "+17" @default.
- Q64187970 P4844 Q2365493 @default.
- Q64187970 P580 "2017-10-05T00:00:00Z" @default.
- Q64187970 P582 "2021-10-07T00:00:00Z" @default.
- Q64187970 P6099 Q42824440 @default.
- Q64187970 P6153 Q1047060 @default.
- Q64187970 P6153 Q1061104 @default.
- Q64187970 P6153 Q1535116 @default.
- Q64187970 P6153 Q23021255 @default.
- Q64187970 P6153 Q2415975 @default.
- Q64187970 P6153 Q28668103 @default.
- Q64187970 P6153 Q30269522 @default.
- Q64187970 P6153 Q30280598 @default.
- Q64187970 P6153 Q309331 @default.
- Q64187970 P6153 Q49112 @default.
- Q64187970 P6153 Q519349 @default.
- Q64187970 P6153 Q681025 @default.
- Q64187970 P6153 Q7914455 @default.
- Q64187970 P8363 Q78089383 @default.